Introduction: Novel Frontiers in Cancer Metastasis

Stanley P. Leong1,2 · Jonathan S. Zager3,4

Received: 15 January 2022 / Accepted: 24 January 2022 / Published online: 22 February 2022
© The Author(s) 2022

Keywords Cancer heterogeneity · Cancer mutations · Cancer microenvironment and metastasis

The 8th International Cancer Metastasis Congress through the Lymphovascular System: Biology & Treatment, was held from October 25–27, 2019 in San Francisco, California. This international conference was inaugurated in 2005 and has been successfully held biennially with several publications summarizing the biology and treatment of cancer metastasis. The last conference in 2017 was summarized in a special issue by Clinical and Experimental Metastasis [1]. The 8th International Cancer Metastasis Congress in October 2019 in San Francisco [2] addressed four major themes including cancer heterogeneity due to mutation [3, 4] with association of formation of neoantigens [5, 6], cancer progression relating to the cancer microenvironment and the mechanisms of metastasis through the lymphatic versus blood vessels and cancer therapy. These major topics are covered in 23 review articles being published online and they have been incorporated into this Special Issue: Novel Frontiers in Cancer Metastasis [7].

Cancer heterogeneity is discussed in the context of Breast Cancer Disparities in Outcomes; Unmasking Biological Determinates Associated with Racial and Genetic Diversity [8] and Cancer Heterogeneity and Metastasis: Life at the Edge [9].

The diversity of cancer biomarkers further validate that cancer is heterogeneous as represented by several review articles on Detection of Cancer Metastasis: Past, Present and Future [10]; Sentinel Lymph Node Biopsy of Melanoma Beyond Histologic Factors [11]; Detection of Melanoma, Breast Cancer and Head and Neck Squamous Cell Cancer Sentinel Lymph Nodes by Tc-99 m Tilmanocept [12]; Cancer Neoantigens as Potential Targets for Immunotherapy [6]; and Current Status of Gastrointestinal Tract Cancer Brain Metastasis and the Use of Blood-based Cancer Biomarker Biopsy [13].

Based on the heterogeneous array of biomarkers, personalized cancer therapy is developed against specific biomarkers for more accurate targeted therapy as represented by the two review articles on Precision Oncology for Breast Cancer through Clinical Trials [14] and Bringing Precision Oncology to Cellular Resolution with Single-Cell Genomics [15].

The role of cancer microenvironment exerts a selective force akin to Darwin’s natural selection [16–18] in the modulation and forging of more aggressive cancer clones to metastasize as reflected in the review article on Cancer Microenvironment and Genomics: Evolution in Process [19].

Cancer clones may escape the primary site and spread initially to the sentinel lymph node as summarized in the Donald L. Morton’s Memorial Lecture: The Legacy of Donald Morton: Past, Present and Future [20] to suggest that sentinel lymph nodes may serve as a major gateway or conduit for cancer metastasis. All the patients with a negative sentinel lymph node biopsy are spared of a radical regional lymph node dissection. The unique role of sentinel lymph nodes in the management of colorectal cancer is addressed by the review article on the Role of Sentinel Lymph Node Mapping in Colon Cancer: Detection of Micrometastasis, Effect on Survival, and Driver of a Paradigm Shift in Extent of Colon Cancer [21].
The molecular mechanism of cancer metastasis through the lymphatic versus blood vessels is still not well understood. An attempt has been made to summarize what we know to date relating to the mechanisms of cancer metastasis in the following review articles on Mechanisms of Breast Cancer Metastasis [22]: The Lymphatic System and Sentinel Lymph Nodes: Conduit for Cancer Metastasis [23]; and Molecular Mechanisms of Cancer Metastasis via the Lymphatic versus the Blood Vessels [24].

The role of lymph node dissection and systemic treatment for a positive sentinel lymph node biopsy are discussed in depth using the model of melanoma, entitled Current Management of Melanoma Patients with Nodal Metastases [25]. In-transit metastasis within the lymphatic vessels is unique in melanoma and it is addressed in The treatment of In-Transit Metastatic Melanoma [26].

Additional novel imaging of cancer is illustrated by Emerging Photoacoustic and Thermoooustic Imaging Techniques for Detecting Primary and Metastatic Cancer and Guiding Therapy [27]. Novel radio-imaging and radiotherapy are discussed in Introduction to Novel Developments in Radio-Imaging and Radiotherapy [28].

Further, innovations in radiotherapy are described in Innovations in Radiotherapy and Advances in Immunotherapy for the Treatment of Brain Metastases [29]. Check point inhibition therapy is discussed in Immunotherapy of Cancer in the Era of Checkpoint Inhibitor [30].

Secondary Lymphedema Related to Cancer Treatment by Surgery or Radiotherapy is an important topic relating to the treatment complication of cancer [31].

The biological events of cancer development with mutation and cancer evolution as well as the molecular mechanisms of cancer metastasis may be more accurately correlated and defined by the adoption of artificial intelligence as summarized in the review article on Empowering Study of Breast Cancer Data with Application of Artificial Intelligence Technology: Promises, Challenges, and Use Cases [32].

This Special Issue: Novel Frontiers in Cancer Metastasis emphasizes that cancer is a heterogeneous disease resulting from genetic mutations or epigenetic changes [33]. Such heterogeneity is characterized by the development of different clones within the primary cancer cell population. Akin to Darwinian “natural selection” [18], the cancer microenvironment including host’s immune responses exerts a selective force to promote the development of aggressive clones to invade and metastasize from the primary site to the distant sites, in accordance to Paget’s seed and soil hypothesis for cancer spread [34], through the lymphatic or blood vessels. Cancer heterogeneity may be present intratumorally, in various sites of metastasis or among patients. Thus, personalized cancer therapy is being developed to treat cancer based on its unique characteristics in relation to each patient. Future molecular and genetic studies with the aid of artificial intelligence may further help us to understand cancer heterogeneity, progression and metastasis with increased precision, thus, allowing the development of more effective therapeutic strategy to control cancer growth.

**Data availability**  Data sharing not applicable to this article as no datasets were generated or analyzed during the current commentary.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Leong SP, Zager JS (2018) Cancer metastasis through the lymphovascular system: biology and treatment. Clin Exp Metastasis 35(5–6):359–561
2. http://www.cancermetastasis.org. Accessed Dec 2021
3. Steuer CE, Ramalingam SS (2018) Tumor mutation burden: leading immunotherapy to the era of precision medicine. J Clin Oncol 36(7):631–632. https://doi.org/10.1200/JCO.2017.76.8770
4. Simpson D, Ferguson R, Martinez CN, Kazlow E, Moran U, Heguy A, Hanniford D, Hernando E, Osman I, Kirchhoff T (2017) Mutation burden as a potential prognostic marker of melanoma progression and survival. J Clin Oncol 35(15):9567–9567. https://doi.org/10.1002/JCO.2017.35.15.supp1.9567
5. Leong SP, Ballesteros-Merino C, Jensen SM, Marwitz S, Bifulco C, Fox BA, Skoberne M (2018) Novel frontiers in detecting cancer metastasis. Clin Exp Metastasis 35(5–6):403–412. https://doi.org/10.1007/s10585-018-9918-6
6. Ma W, Pham B, Li T (2021) Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10091-1
7. Leong SP, Zager JS (2022) Novel frontiers in cancer metastasis. Clin Exp Metastasis 35:403
8. Martini R, Newman L, Davis M (2021) Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity. Clin Exp Metas. https://doi.org/10.1007/s10585-021-10087-x
9. Gillies RJ (2021) Cancer heterogeneity and metastasis: life at the edge. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10101-2
10. Alix-Panabieres C, Magliocco A, Cortes-Hernandez LE, Eslami SZ, Franklin D, Messina JL (2021) Detection of cancer metastasis: past, present and future. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10088-w
11. Carr MJ, Monzon FA, Zager JS (2021) Sentinel lymph node biopsy in melanoma: beyond histologic factors. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10089-9
12. Leong SP (2021) Detection of melanoma, breast cancer and head and neck squamous cell cancer sentinel lymph nodes by Tc-99m tilmanocept. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10137-4

 Springer
13. Shoji Y, Furuhashi S, Kelly DF, Bilchik AJ, Hoon DS, Bustos MA (2021) Current status of gastrointestinal tract cancer brain metastasis and the use of blood-based cancer biomarker biopsy. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10094-y

14. Blucher AS, Mills GB, Tsang YH (2021) Precision oncology for breast cancer through clinical trials. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10092-0

15. Xia Y, Gawad C (2021) Bringing precision oncology to cellular resolution with single-cell genomics. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10129-4

16. Hellman S (1997) Darwin’s clinical relevance. Cancer 79(12):2275–2281. https://doi.org/10.1002/(sici)1097-0142(19970615)79:12%3c2275::aid-cncr1%3e3.0.co;2-l

17. Greaves M (2001) Cancer: the evolutionary legacy. Oxford University Press, Oxford

18. Darwin C (1859) The origin of species. London

19. Leong SP, Witz IP, Sagi-Assif O, Izraely S, Sleeman J, Piening B, Fox BA, Bifulco CB, Martini R, Newman L (2021) Cancer microenvironment and genomics: evolution in process. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10097-9

20. Faries MB (2021) Donald L. Morton Memorial lecture: the legacy of Donald Morton: past, present and future. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10110-1

21. Saha S, Philimon B, Efeson M, Helina A, Elgamal M, Kiya G, Hilkiah S, Arora M, Wiese D, Kitagawa Y (2021) The role of sentinel lymph node mapping in colon cancer: detection of micrometastasis, effect on survival, and driver of a paradigm shift in extent of colon resection. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10121-y

22. Nathanson SD, Detmar M, Padera TP, Yates LR, Welch DR, Beadnell TC, Scheid AD, Wrenn ED, Cheung K (2021) Mechanisms of breast cancer metastasis. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10090-2

23. Leong SP, Pissas A, Scarato M, Gallon F, Pissas MH, Amore M, Wu M, Faries MB, Lund AW (2021) The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10123-w

24. Leong SP, Naxerova K, Keller L, Pantel K, Witte M (2021) Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10120-z

25. Han D, van Akkooi ACJ, Straker RJ 3rd, Shannon AB, Karakousis GC, Wang L, Kim KB, Reintgen D (2021) Current management of melanoma patients with nodal metastases. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10099-7

26. Patel A, Carr MJ, Sun J, Zager JS (2021) In-transit metastatic cutaneous melanoma: current management and future directions. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10100-3

27. Witte RS, Tamimi EA (2021) Emerging photoacoustic and thermoacoustic imaging technologies for detecting primary and metastatic cancer and guiding therapy. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10095-x

28. Stea B, Witte RS (2021) Introduction to novel developments in radio-imaging and radiotherapy. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10114-x

29. Ho Q-A, Stea B (2021) Innovations in radiotherapy and advances in immunotherapy for the treatment of brain metastases. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10104-z

30. Mehmi I, Hamid O (2021) Immunotherapy of cancer in the era of checkpoint inhibitor. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10132-9

31. Bernas M, Thiadens SR, Stewart P, Granzow J (2021) Secondary lymphedema from cancer therapy. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10096-w

32. Panahiazar M, Chen N, Lituev D, Hadley D (2021) Empowering study of breast cancer data with application of artificial intelligence technology: promises, challenges, and use cases. Clin Exp Metastasis. https://doi.org/10.1007/s10585-021-10125-8

33. Iacobuzio-Donahue CA (2008) Epigenetic changes in cancer. Ann Rev Pathol Mech Dis 3:229–249. https://doi.org/10.1146/annurev.pathol.3.121806.151442

34. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133(3421):571–573

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.